BioNTech and DualityBio’s Antibody-Drug Conjugate Trastuzumab Pamirtecan Demonstrated Clinically Meaningful Efficacy in Patients with HER2-Expressing, Recurrent Endometrial Cancer

AI Briefing

• – Trastuzumab pamirtecan shows clinical efficacy in HER2+ recurrent endometrial cancer patients.
• – Positive results from Phase 2 trial with BioNTech's antibody-drug conjugate.
• – BioNTech announces promising findings for trastuzumab pamirtecan in HER2+ endometrial cancer.